ArticleBMC bioinformatics2019
DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug-drug interactions.
Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 68 citations in OpenAlex.
- Advancing Drug-Drug Interaction Prediction with Biomimetic Improvements: Leveraging the Latest Artificial Intelligence Techniques to Guide Researchers in the Field.Biomimetics (Basel, Switzerland) · 2026Review
- Improving drug repositioning with negative data labeling using large language models.Journal of cheminformatics · 2025Article
- Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery.International journal of molecular sciences · 2024Article
- Construction and application of medication reminder system: intelligent generation of universal medication schedule.BioData mining · 2024Article
- Positive-unlabeled learning to infer protection status and identify correlates in vaccine efficacy field trials.iScience · 2024Article
- Multimodal CNN-DDI: using multimodal CNN for drug to drug interaction associated events.Scientific reports · 2024Article
- BatmanNet: bi-branch masked graph transformer autoencoder for molecular representation.Briefings in bioinformatics · 2023Article
- Structural Dynamics Predominantly Determine the Adaptability of Proteins to Amino Acid Deletions.International journal of molecular sciences · 2023Article
- Prediction of Proteins in Cerebrospinal Fluid and Application to Glioma Biomarker Identification.Molecules (Basel, Switzerland) · 2023Article
- Predicting drug characteristics using biomedical text embedding.BMC bioinformatics · 2022Article
- Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes.Journal of cheminformatics · 2022Article
- DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety.Nucleic acids research · 2022Article
- Advancement in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources.Journal of the American Medical Informatics Association : JAMIA · 2021Article
- DPDDI: a deep predictor for drug-drug interactions.BMC bioinformatics · 2020Article
- Integrated Random Negative Sampling and Uncertainty Sampling in Active Learning Improve Clinical Drug Safety Drug-Drug Interaction Information Retrieval.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-drug interactions (DDIs) are a major concern in patients' medication. It's unfeasible to identify all potential DDIs using experimental methods which are time-consuming and expensive. Computational methods provide an effective strategy, however, facing challenges due to the lack of experimentally verified negative samples.
resultsTo address this problem, we propose a novel positive-unlabeled learning method named DDI-PULearn for large-scale drug-drug-interaction predictions. DDI-PULearn first generates seeds of reliable negatives via OCSVM (one-class support vector machine) under a high-recall constraint and via the cosine-similarity based KNN (k-nearest neighbors) as well. Then trained with all the labeled positives (i.e., the validated DDIs) and the generated seed negatives, DDI-PULearn employs an iterative SVM to identify a set of entire reliable negatives from the unlabeled samples (i.e., the unobserved DDIs). Following that, DDI-PULearn represents all the labeled positives and the identified negatives as vectors of abundant drug properties by a similarity-based method. Finally, DDI-PULearn transforms these vectors into a lower-dimensional space via PCA (principal component analysis) and utilizes the compressed vectors as input for binary classifications. The performance of DDI-PULearn is evaluated on simulative prediction for 149,878 possible interactions between 548 drugs, comparing with two baseline methods and five state-of-the-art methods. Related experiment results show that the proposed method for the representation of DDIs characterizes them accurately. DDI-PULearn achieves superior performance owing to the identified reliable negatives, outperforming all other methods significantly. In addition, the predicted novel DDIs suggest that DDI-PULearn is capable to identify novel DDIs.
conclusionsThe results demonstrate that positive-unlabeled learning paves a new way to tackle the problem caused by the lack of experimentally verified negatives in the computational prediction of DDIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.